5-Amino-1MQ: Evidence, Safety, and Research Status

5-Amino-1MQ—also written 5A1MQ or 5-amino-1-methylquinolinium—is an experimental small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is not a peptide, an FDA-approved drug, or a clinically established weight-loss or longevity treatment. Published efficacy findings are preclinical: principally cell experiments and diet-induced-obesity mouse models.

Profile summary

Identity and proposed mechanism

NNMT transfers a methyl group from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide. Laboratory studies use 5-Amino-1MQ to inhibit this enzyme and examine downstream changes in metabolites associated with nicotinamide, NAD+ salvage, and methyl-donor pathways.

That mechanism is often compressed online into claims that 5-Amino-1MQ “boosts NAD+” or “reprograms fat cells.” Those phrases omit important limits: measured biochemical changes depend on the model, tissue, exposure, and assay, and a mechanistic signal is not evidence of improved energy, fat loss, healthy aging, or disease treatment in people.

Evidence by model

Cell studies

The initial small-molecule work found that NNMT inhibitors lowered intracellular 1-methylnicotinamide, altered NAD+- and methionine-cycle metabolites, and suppressed lipogenesis in cultured adipocytes. More recent experiments have used 5-Amino-1MQ in other cell systems, including primary human-derived cells, but treating isolated cells is not a clinical exposure study.

Mouse studies

In diet-induced-obesity mouse models, investigators reported changes in weight or fat-mass gain, glucose tolerance, insulin sensitivity, liver fat, and selected circulating markers. Follow-up work also studied 5-Amino-1MQ together with a lower-calorie diet and characterized mouse pharmacokinetics and tissue distribution.

These studies test a pharmacologic hypothesis in mice. They do not establish a safe human dose, route, treatment duration, durable benefit, or risk-benefit balance. Results from an injected mouse intervention also cannot establish that an oral product marketed online is absorbed or behaves similarly.

What has not been established

Published human clinical evidence has not established that 5-Amino-1MQ:

• causes weight loss or improves body composition in people;
• improves fatigue, exercise performance, or metabolic health;
• raises tissue NAD+ to a clinically meaningful degree;
• slows aging or extends human lifespan;
• treats obesity, fatty-liver disease, diabetes, or another medical condition; or
• is safe by oral, injectable, or any other administration route.

An absence of a demonstrated adverse effect in a short animal experiment is not evidence of human safety. Human pharmacokinetics, interactions, reproductive toxicity, chronic toxicity, and risks from sustained NNMT inhibition remain insufficiently characterized.

FDA and compounding status

5-Amino-1MQ has no FDA-approved drug product or indication. In a January 2026 warning letter, FDA stated that 5-amino-1-methylquinolinium iodide did not appear on the section 503B bulks list and was not being used to compound a drug on the shortage list; products made from it therefore were not eligible for the cited section 503B exemptions.

That finding is about federal compounding conditions, not evidence that products sold as “research use only” are approved, standardized, safe, or effective. A pharmacy label or vendor certificate also does not substitute for an approved application or clinical evidence.

Research-quality checklist

For analytical or laboratory research, verify:

1. the complete chemical name and molecular form, including whether a counterion such as iodide is present;
2. identity evidence, such as mass spectrometry or NMR, separately from chromatographic purity;
3. lot-specific assay and net content rather than relying on total container mass;
4. related substances, residual solvents, water, elemental impurities, and counterion content;
5. storage and stability evidence for the exact form and matrix;
6. whether the reference study used the same compound, formulation, route, and model; and
7. that a “purity” percentage alone does not demonstrate sterility, bioavailability, or suitability for administration.

The peptide purity-testing guide explains common analytical terms that also matter when evaluating non-peptide research compounds. The source directory organizes public documentation signals, while the sourcing policy explains why inclusion is not an endorsement for human use. The research methodology describes how evidence grades are assigned.

References

1. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018.
2. Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific Reports. 2021.
3. Neelakantan H, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in diet-induced obese mice. Scientific Reports. 2022.
4. Willows SJ, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Journal of Pharmacy and Pharmacology. 2024.
5. US Food and Drug Administration. GenoGenix LLC warning letter. 2026.

Bottom line

5-Amino-1MQ is an experimental NNMT-inhibiting small molecule with an interesting preclinical metabolic signal. It is not a peptide, and human efficacy, safety, dosing, and long-term consequences remain unestablished. Conclusions should stay tied to the exact cell or mouse experiment instead of converting early pharmacology into a weight-loss or longevity protocol.